| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Collaboration revenue | 1,090 | 1,460 | 2,550 | |
| Research and development expense | 13,820 | 21,031 | 19,739 | |
| General and administrative | 6,507 | 7,631 | 7,831 | |
| Total operating expenses | 20,327 | 28,662 | 27,570 | |
| Loss from operations | -19,237 | -27,202 | -25,020 | |
| Other income, net | 1,176 | 1,433 | 1,633 | |
| Total other income, net | 1,176 | 1,433 | 1,633 | |
| Loss before benefit (provision) for income taxes | -18,061 | -25,769 | -23,387 | |
| Benefit (provision) for income taxes | 0 | 1 | - | |
| Net loss | -18,061 | -25,770 | -23,387 | |
| Unrealized gain (loss) on available-for-sale marketable securities | 48 | -74 | -3 | |
| Foreign currency translation adjustments, net | 11 | 13 | 1 | |
| Comprehensive loss | -18,024 | -25,857 | -23,391 | |
| Net loss per share, basic | -1.92 | -2.74 | -2.49 | |
| Net loss per share, diluted | -1.92 | -2.74 | -2.49 | |
| Weighted average number of shares outstanding, basic | 9,391,559 | 9,390,542 | 9,384,266 | |
| Weighted average number of shares outstanding, diluted | 9,391,559 | 9,390,542 | 9,384,266 | |
Korro Bio, Inc. (KRRO)
Korro Bio, Inc. (KRRO)